Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13625892 | 0.91 | GRIN2B (0.40) | GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL13625862 | 0.91 | GRIN2B (0.34) | GRIN2B | |
| SCHEMBL13625768 | 0.87 | ADORA3 (0.32) | SMN1; SMN2CYP3A4 | |
| SCHEMBL13625766 | 0.86 | GRIN2B (0.35) | GRIN2BSMN1; SMN2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL8932185 | 0.85 | GRIN2B (0.41) | GRIN2B | |
| SCHEMBL13819686 | 0.84 | MEN1 (0.31) | SMN1; SMN2CYP3A4 | |
| SCHEMBL13819677 | 0.84 | MEN1 (0.33) | SMN1; SMN2CYP3A4 | |
| SCHEMBL14393656 | 0.83 | ADORA3 (0.33) | — | |
| SCHEMBL12010054 | 0.83 | MEN1 (0.31) | SMN1; SMN2CYP3A4 | |
| SCHEMBL13819685 | 0.83 | MEN1 (0.31) | SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | GRIN2B 453/4885SMN1; SMN2 3971/4885CYP2C19 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.